Compare KNF & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KNF | IDYA |
|---|---|---|
| Founded | 1917 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.6B |
| IPO Year | 2023 | 2019 |
| Metric | KNF | IDYA |
|---|---|---|
| Price | $64.39 | $40.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 16 |
| Target Price | ★ $97.25 | $52.86 |
| AVG Volume (30 Days) | ★ 899.1K | 682.5K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,146,012,000.00 | $218,710,000.00 |
| Revenue This Year | $8.93 | N/A |
| Revenue Next Year | $5.28 | $201.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 8.52 | ★ 3024.43 |
| 52 Week Low | $58.72 | $23.23 |
| 52 Week High | $96.28 | $42.68 |
| Indicator | KNF | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 38.35 | 64.18 |
| Support Level | N/A | $33.23 |
| Resistance Level | $80.09 | N/A |
| Average True Range (ATR) | 2.28 | 1.29 |
| MACD | 0.42 | 0.37 |
| Stochastic Oscillator | 35.80 | 73.15 |
Knife River Corp is a people-first construction materials and contracting services company. It provides construction materials and contracting services to build safe roads, bridges, airport runways, and other critical infrastructure needs that connect people. The group is a provider of crushed stone, sand, and gravel in the United States. It operates through four reportable segments: West, Mountain, Central, and Energy Services.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.